Amarin Corporation PLC
Change company Symbol lookup
Select an option...
AMRN Amarin Corporation PLC
UAVS Ageagle Aerial Systems Inc
IWSY ImageWare Systems Inc
AMPX Amprius Technologies Inc
TNC Tennant Co
CVX Chevron Corp
ACGLO Arch Capital Group Ltd
AAPL Apple Inc
BCSF Bain Capital Specialty Finance Inc
HPE Hewlett Packard Enterprise Co
Go

Health Care : Biotechnology |
Based in Ireland
Company profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$1.27
Day's Change
0.03 (2.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.31
Day's Low
1.22
Volume
(Heavy Day)

Today's volume of 1,175,597 shares is on pace to be much greater than AMRN's 10-day average volume of 1,820,703 shares.

1,175,597
Historical quotes & splits
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

3rd Party Research Disclosure